N/A N=441 Randomized Supportive Care

Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma

Stage 0 Skin Melanoma · Stage I Skin Melanoma · Stage IA Skin Melanoma · Stage IB Skin Melanoma · Stage II Skin Melanoma

Bottom Line

View on ClinicalTrials.gov: NCT03028948 ↗

Enrolled (actual)

441

Serious AEs

—

Results posted

Feb 2023

Primary outcome: Primary: Sun Protection Behavior Index — 3.54; 3.37 scores on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Internet-Based Intervention (Other); Questionnaire Administration (Other); Survey Administration (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Rutgers, The State University of New Jersey
Primary completion: Aug 2020

Outcome Measures

Outcome	Result	p-value
PRIMARY Sun Protection Behavior Index	3.65; 3.52	—
PRIMARY Number of Participants That Performed a Thorough Skin Self-examination (SSE) in the Past 2 Months	59; 16; 139; 199	—
SECONDARY Performance of Thorough Skin-self-examination (SSE) in the Past 4 Months	54; 24; 132; 182; 3; 1	—
SECONDARY Performance of Thorough Skin-self-examination (SSE) in the Past 6 Months	54; 26; 121; 169; 5; 7	—
SECONDARY Number of SSEs Performed	—	—
SECONDARY Number of Body Areas Examined	—	—
SECONDARY Use of Tools to Facilitate SSE	—	—
SECONDARY Frequency of Engaging in Each Individual Sun Protection Behavior From the Sun Protection Behavior Index	—	—
SECONDARY Number of Sunburns	—	—
SECONDARY Wearing Long Pants	—	—
SECONDARY Wearing Sunglasses	—	—
SECONDARY Sunbathing	—	—
SECONDARY Sun Protection Behavior Index	3.65; 3.52	—
SECONDARY Sun Protection Behavior Index	3.65; 3.52	—
SECONDARY Sun Protection Behavior Index	3.65; 3.52	—

Summary

This clinical trial studies how well an interactive tailored website works in promoting sun protection and skin self-check behaviors in patients with stage 0-III melanoma. An internet-based program may help individuals to perform skin self-checks and engage in sun protection behaviors.

Eligibility Criteria

Inclusion Criteria

Phase I: Diagnosis of primary pathologic stage 0-III cutaneous malignant melanoma
Phase I: From 3-36 months post-surgical treatment
Phase I: Access to the internet
Phase I: Able to speak and read English
Phase I: Able to provide informed consent
Phase II: Diagnosis of primary pathologic stage 0-III cutaneous malignant melanoma
Phase II: From 3-24 months post-surgical treatment
Phase II: Not adherent to thorough SSE (i.e., did not check every area of the body at least once during the past 2 months)
Phase II: Not adherent to sun protection recommendations (i.e., mean score < 4 [which corresponds to "often"] on a 5-point scale [from 1 = "never" to 5 = "always"] that assesses the frequency of engaging in four sun protection behaviors)
Phase II: Access to a computer connected to the internet
Phase II: Able to speak and read English
Phase II: Able to provide informed consent

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03028948). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.